RY 175.39 0.5907% SHOP 144.24 1.7064% TD 93.26 3.7375% ENB 62.645 -0.8782% BN 79.18 0.2659% TRI 268.7 -0.6397% CNQ 42.57 -0.0939% CP 111.4 -0.8191% CNR 146.8 -0.2243% BMO 143.57 0.1605%
RY 175.39 0.5907% SHOP 144.24 1.7064% TD 93.26 3.7375% ENB 62.645 -0.8782% BN 79.18 0.2659% TRI 268.7 -0.6397% CNQ 42.57 -0.0939% CP 111.4 -0.8191% CNR 146.8 -0.2243% BMO 143.57 0.1605%

Big Pharma Split Corp Class A

Financial Services CA PRM

11.68CAD
-0.02(0.17%)

Last update at 2025-05-21T18:41:00Z

Day Range

11.6811.68
LowHigh

52 Week Range

12.1714.69
LowHigh

Fundamentals

  • Previous Close 11.70
  • Market Cap14.92M
  • Volume25
  • P/E Ratio13.33
  • Dividend Yield8.81%
  • Revenue TTM0.32M
  • Revenue Per Share TTM0.26
  • Gross Profit TTM 5.56M
  • Diluted EPS TTM0.99

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

2018-12-312019-12-312020-12-312021-12-312022-12-310M0.5M1M1.5M2M2.5M3M3.5M4M4.5M5M5.5M
Total Revenue
Net Income

Balance Sheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M5M10M15M20M25M30M35M
Total Assets
Total Liabilities

Change in Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-1.4M-1.2M-1M-0.8M-0.6M-0.4M-0.2M0M0.2M0.4M0.6M0.8M1M1.2M

Total Operating Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-10M-8M-6M-4M-2M0M2M4M6M8M10M

Dividends Paid

2018-12-312019-12-312020-12-312021-12-312022-12-310M0.2M0.4M0.6M0.8M1M1.2M1.4M1.6M1.8M2M2.2M2.4M2.6M2.8M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 3.15M 4.85M 0.27M 3.14M 2.78M
Minority interest - - - - -
Net income 3.15M 4.85M 0.27M 5.83M -0.38855M
Selling general administrative 0.36M 0.37M 0.22M 0.29M 0.32M
Selling and marketing expenses - - - - -
Gross profit 3.71M 5.36M 0.59M 2.20M 2.96M
Reconciled depreciation - - - - -
Ebit - 4.61M 0.27M 3.14M 5.95M
Ebitda 3.15M 4.85M 0.27M 0.45M 9.12M
Depreciation and amortization - - - - 3.17M
Non operating income net other - - - - -
Operating income 3.15M 4.85M 0.27M 0.45M 5.95M
Other operating expenses 0.57M 0.51M 0.32M 0.63M 0.73M
Interest expense - 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -2.68964M 3.17M
Total revenue 3.71M 5.36M 0.59M 2.43M 3.23M
Total operating expenses 0.57M 0.51M 0.32M 0.40M 0.45M
Cost of revenue - - - 0.24M 0.27M
Total other income expense net - - - 2.69M -3.16863M
Discontinued operations - - - - -
Net income from continuing ops 3.15M 4.85M 0.27M 3.14M 2.78M
Net income applicable to common shares - 4.21M -0.21739M 2.58M 2.10M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 26.53M 39.10M 37.81M 22.93M 27.18M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.72M - 0.81M 0.04M 0.24M
Total liab 0.25M 19.37M 15.41M 0.21M 10.87M
Total stockholder equity 15.85M 19.73M 22.40M 13.19M 16.31M
Deferred long term liab - - - - -
Other current liab -0.24868M -0.34784M -0.33902M -0.21322M 10.87M
Common stock 15.85M - 22.40M 13.19M 16.31M
Capital stock - - - - -
Retained earnings - - - - -
Other liab - - - - -
Good will - - - - -
Other assets - - 0.15M 0.15M -
Cash 0.20M 0.82M 1.43M 0.23M 0.54M
Cash and equivalents - - - - -
Total current liabilities 0.25M 0.35M 0.34M 0.21M 10.87M
Current deferred revenue -10.04870M - - - -
Net debt 10.09M -0.81921M -1.42982M -0.23099M -0.53606M
Short term debt 10.30M - - - 26.33M
Short long term debt - - - - -
Short long term debt total 10.30M - - - -
Other stockholder equity - - 22.40M - -
Property plant equipment - - - - -
Total current assets 0.28M 14.82M 1.53M 0.34M 27.18M
Long term investments 26.25M 24.27M 36.13M 22.45M -
Net tangible assets - - 22.40M 13.19M 16.31M
Short term investments 25.54M - - - 26.33M
Net receivables 0.08M 14.00M 0.10M 0.10M 0.07M
Long term debt - - - - -
Inventory -0.71824M - - - -
Accounts payable 0.25M 0.35M 0.34M 0.21M -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -26.25326M -24.27309M -36.13086M -22.44624M 0.00000M
Deferred long term asset charges - - - - -
Non current assets total 26.25M 24.27M 36.13M 22.45M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - - - - -
Change to liabilities - 0.00000M 0.00000M 0.00000M 0.00000M
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities -1.73730M 10.19M -4.65203M -8.56934M -2.70952M
Change to operating activities - -0.15429M -0.03168M -0.00301M -0.05396M
Net income 2.39M 4.21M -0.21739M 2.58M 2.10M
Change in cash -0.61061M 1.20M -0.30506M 0.12M -1.42845M
Begin period cash flow 1.43M 0.23M 0.54M 0.42M 1.85M
End period cash flow 0.82M 1.43M 0.23M 0.54M 0.42M
Total cash from operating activities 1.13M -9.00036M 4.35M 8.68M 1.27M
Issuance of capital stock 0.88M 13.32M - - 0.00000M
Depreciation - - - - -
Other cashflows from investing activities - - - - -
Dividends paid 2.62M 2.84M 1.73M 2.08M 2.25M
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - -2.92095M -6.48549M -0.45609M
Other cashflows from financing activities 0.48M 5.46M -0.29107M -0.29107M -0.29107M
Change to netincome - -13.05582M 4.60M 6.10M -0.78022M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.18M -0.15429M -0.03168M -0.00301M -0.05396M
Stock based compensation - - - - -
Other non cash items -1.43645M -13.05582M 4.60M 6.10M -0.78022M
Free cash flow 1.13M -9.00036M 4.35M 8.68M 1.27M

Peer Comparison

Sector: Financial Services Industry: Asset Management

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PRM
Big Pharma Split Corp Class A
-0.02 0.17% 11.68 13.33 - 46.52 0.94 6.89 -2.4541
BN
Brookfield Corporation
0.21 0.27% 79.18 100.56 12.82 1.23 2.10 3.32 10.38
BAM
Brookfield Asset Management Ltd
-0.15 0.19% 79.30 51.98 30.67 58.11 7.37 61.42 46.15
PHYS
Sprott Physical Gold Trust
-0.32 0.91% 34.85 6.64 - 6.67 1.14 6.62 0.66
IGM
IGM Financial Inc.
0.24 0.54% 44.47 12.06 10.57 2.83 1.40 5.14 13.59

Reports Covered

Stock Research & News

Profile

Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.

Big Pharma Split Corp Class A

610 Chartwell Road, Oakville, ON, Canada, L6j 4A5

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.